{"prompt": "['Study Number: GSP 301-305', 'Version 3.0', 'Date 18-Jul-2018', \"may also discontinue the subject's study participation at any time at his/her discretion and for\", 'any reason.', 'The reasons for subject withdrawal will be recorded and may include, but are not limited to:', '1.', 'Withdrawal of consent/assent by the subject (or parent/legal guardian, as applicable) to', 'continue in the study. If consent is withdrawn, the subject will not receive any further', 'investigational product (IP) or further study observation. Note that the subject may need', 'to undergo additional tests or tapering of treatment to withdraw safely, as applicable.', '2. Development of a serious or intolerable AE that necessitates discontinuation at the', 'discretion of the Investigator (the AE section of the CRF/eCRF must be completed; AE', 'includes serious adverse event (SAE) and death.', '3. At the discretion of the Investigator, when he/she believes continued participation is not', 'in the best interest of the subject.', '4. At the discretion of the Investigator, when the subject does not adhere to the study', 'procedures.', '5. A protocol deviation that, in the opinion of the Sponsor and Investigator, warrants', 'discontinuation from the study.', '7.4.1.', 'Lost to Follow-up', 'A subject will be considered lost-to-follow-up only if no contact has been established by the time', \"the study is completed such that there is insufficient information to determine the subject's status\", 'on the Final Visit/Discontinuation Visit 4 (Table 2). Subjects refusing to return to the site or to', 'continue participation in the study should be documented as \"withdrawal of consent\" rather than', '\"lost to follow-up.\" Investigators should document attempts to re-establish contact with missing', 'subjects throughout the study period. If contact with a missing subject is re-established, the', 'subject should not be considered lost-to-follow-up and any evaluations should resume according', 'to the protocol.', 'If the subject withdraws consent for the study, no further evaluation will be performed and no', 'additional data or medical records will be collected. The Sponsor may retain and continue to use', 'any data collected before withdrawal of consent.', 'A subject who discontinues study drug early but does not withdraw consent, should return for', 'end of study assessments, as noted in Section 12.5.', 'The Investigator will:', 'inquire about the reason for withdrawal,', 'request that the subject return all unused IP, and', 'request that the subject return for the Final Visit/Discontinuation Visit (Visit 4),', 'including examinations and clinical laboratory measurements, as applicable.', 'If the subject refuses to attend the clinic, efforts will be made and documented, to perform the', 'end of study assessments; collection of visit data during a telephone call is permitted, as', 'applicable.', 'Glenmark', 'CONFIDENTIAL', 'Page 36 of 90']['Study Number: GSP 301-305', 'Version 3.0', 'Date 18-Jul-2018', 'The Investigator must request follow up with the subject regarding any unresolved AEs/SAEs.', 'At a minimum, at the end of the study, the Investigator should consult public records to', \"determine the subject's circumstances, eg, vital status, incarceration, or relocation.\", '7.4.2.', 'Permanent Discontinuation of Study Drug', 'A subject who is permanently discontinued from further receipt of study drug, regardless of the', 'reason (withdrawal of consent, due to an AE, other), will be identified as having permanently', 'discontinued treatment. Subjects who permanently discontinue treatment will be considered not', 'to have completed the study as outlined in the protocol (see Section 8.5 and Section 12.5).', '7.4.3.', 'Replacement of Subjects', 'Discontinued subjects will not be replaced.', '8.', 'TREATMENT OF SUBJECTS', '8.1.', 'Description of Study Drug', 'The following study drugs will be supplied by Glenmark for the study:', 'Table 3:', 'Study Drugs', 'GSP 301-305', 'Product Name', 'FDC of olopatadine hydrochloride', 'g and', 'mometasone furoate', 'g NS', 'Manufacturing License Name', 'GSP 301', 'NS', 'Dosage Form', 'Spray, metered (nasal spray)', 'Dosage', 'in each nostril', 'Dose frequency', 'for 14 days', 'Route of Administration', 'Intranasal', 'Manufacturer', 'Glenmark', 'Placebo', 'Product Name', 'GSP 301 Placebo NS', 'Manufacturing License Name', 'GSP 301 Placebo NS', 'Dosage Form', 'Spray, metered (nasal spray)', 'Dosage', 'in each nostril', 'Dosage frequency', 'for 14 days', 'Route of Administration', 'Intranasal', 'Manufacturer', 'Glenmark', 'BID = twice daily; FDC = fixed dose combination; NS = nasal spray', 'See Section 9 for additional information on study drug supplies.', 'Glenmark', 'CONFIDENTIAL', 'Page 37 of 90']\n\n###\n\n", "completion": "END"}